Announcements Trials
Browse Landscape

Phase

Phase 2 39Phase 3 6Phase 1/2 4Phase NA 3Phase 4 3Phase 2/3 3

Status

Recruiting 15Completed 7Not yet recruiting 6Unknown 5Active not recruiting 3

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 1Head & Neck 1

Conditions

Carcinoma, Hepatocellular 3Resectable Non-small Cell Lung Cancer 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Esophageal Squamous Cell Carcinoma 1

Interventions

Paclitaxel 24Oxaliplatin 24Capecitabine 24Gemcitabine 21Cisplatin 21Fluorouracil 20Drug Therapy 18Docetaxel 18Carboplatin 17pembrolizumab 15Leucovorin 15Irinotecan 15Radiotherapy 12tislelizumab 11Magnetic Resonance Spectroscopy 10Bevacizumab 10Specimen Handling 9Pemetrexed 9Radiation 8Injections 8Cetuximab 8toripalimab 7Surgical Procedures, Operative 7Radiotherapy, Intensity-Modulated 7Azacitidine 7venetoclax 6sintilimab 6Trastuzumab 6Topotecan 6Standard of Care 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Not yet recruiting × sintilimab × Clear all
NCT07537946 2026-04-17

Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer

Tongji Hospital

Phase 3 Not yet recruiting
400 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Neoplasm Metastasis

NCT06900218 2025-04-02

PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 3 Not yet recruiting
664 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT06485557 2024-07-03

A Prospective Cohort Study of Neoadjuvant Chemotherapy Plus Sintillumab in the Treatment of Resectable NSCLC

Tang-Du Hospital

Phase 3 Not yet recruiting
90 enrolled
Thoracic

Resectable Non-small Cell Lung Cancer

NCT06089369 2024-04-30

Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion

Tongji Hospital

Phase 3 Not yet recruiting
360 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT06089382 2023-10-18

A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection

Tongji Hospital

Phase 3 Not yet recruiting
104 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT05244798 2022-10-25

Sintilimab Plus NCT or NCRT Versus NCRT for ESCC

Sichuan Cancer Hospital and Research Institute

Phase 3 Not yet recruiting
420 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡